BioTelemetry's total inventories for the quarter that ended in Sep. 2020 was $5.5 Mil. BioTelemetry's average total inventories from the quarter that ended in Jun. 2020 to the quarter that ended in Sep. 2020 was $6.2 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. BioTelemetry's Net-Net Working Capital per share for the quarter that ended in Sep. 2020 was $-5.65.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
BioTelemetry's Days Inventory for the
three
months ended in Sep. 2020 was 12.46.
Inventory Turnover measures how fast the company turns over its inventory within a year.
BioTelemetry's Inventory Turnover for the quarter that ended in Sep. 2020 was 7.33.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
BioTelemetry's Inventory-to-Revenue for the quarter that ended in Sep. 2020 was 0.05.
BioTelemetry Total Inventories Historical Data
The historical data trend for BioTelemetry's Total Inventories can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
BioTelemetry (NAS:BEAT) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
BioTelemetry's Net-Net Working Capital Per Share for the quarter that ended in Sep. 2020 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
BioTelemetry's Inventory to Revenue for the quarter that ended in Sep. 2020 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
BioTelemetry Total Inventories Related Terms
Thank you for viewing the detailed overview of BioTelemetry's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.
BioTelemetry Inc provides monitoring services and digital population health management for healthcare providers, medical device manufacturing, and centralized core laboratory services for clinical research. It operates under healthcare, technology, and research segments. The Healthcare segment is focused on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders. The Research segment is engaged in central core laboratory services providing cardiac monitoring, imaging services, scientific consulting and data management services for drug and medical device trials and the Technology segment, focuses on the development, manufacturing, testing, and marketing of cardiovascular and blood glucose monitoring devices to medical companies, clinics and hospitals.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BEAT has been successfully added to your 